Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MIRA Pharmaceuticals, Inc. ( (MIRA) ) just unveiled an update.
On March 23, 2026, MIRA Pharmaceuticals reported new preclinical data showing that its oral candidate Mira-55 did not produce THC- or rimonabant-like central nervous system or behavioral side effects in standard assays of psychogenic, motor, and anxiety-related effects. Across tested doses, the drug showed no sedation, catalepsy, or motor impairment, and it demonstrated reduced anxiety-like behavior in the Elevated Plus Maze, while performing comparably to controls in Open Field testing.
These findings build on earlier preclinical results in which Mira-55 delivered morphine-comparable pain relief in a validated inflammatory pain model without opioid-related risks, restoring pain thresholds to near-baseline levels. Collectively, the data support MIRA’s plan to advance Mira-55 toward an Investigational New Drug submission for inflammatory pain, potentially strengthening the company’s position in non-opioid pain management if future clinical trials confirm these benefits.
The most recent analyst rating on (MIRA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel cannabinoid-related therapeutics. Its lead candidate, Mira-55, targets inflammatory pain with the aim of achieving strong analgesic effects while avoiding the safety and dependency issues associated with opioids and certain cannabinoid agents.
Average Trading Volume: 151,994
Technical Sentiment Signal: Sell
Current Market Cap: $38.53M
For a thorough assessment of MIRA stock, go to TipRanks’ Stock Analysis page.